Tag: MONOGRAPH

  • Honokiol

    Biphenyl neolignan polyphenol with pleiotropic GABAA receptor positive allosteric modulation, SIRT3 activation, and multi-pathway anti-inflammatory and antineoplastic activity

    A naturally occurring biphenolic neolignan isolated from Magnolia officinalis bark, distinguished by positive allosteric modulation of GABAA receptors, direct activation of mitochondrial sirtuin-3, and broad-spectrum preclinical activity across oncology, neuroprotection, anxiolysis, and inflammation.

    Abstract

    Honokiol (3′,5-di-2-propenyl-1,1′-biphenyl-2,4′-diol) is a biphenyl neolignan polyphenol isolated principally from the bark, seed cones, and leaves of Magnolia officinalis and related species of the genus Magnolia, a botanical source with documented use in traditional Chinese, Japanese, and Korean medicine for over two thousand years. The compound has attracted substantial modern pharmacological interest owing to a pleiotropic mechanism profile that includes positive allosteric modulation of both synaptic and extrasynaptic GABAA receptors at a site distinct from the benzodiazepine binding site; direct activation of the mitochondrial deacetylase sirtuin-3 (SIRT3) with consequent enhancement of mitochondrial respiration, ATP production, and antioxidant defense; agonism at peroxisome proliferator-activated receptor gamma (PPARgamma); inhibition of nuclear factor kappa-B (NF-kB) and signal transducer and activator of transcription 3 (STAT3) signaling; modulation of the PI3K/Akt/mTOR axis; and disruption of the PSD95-nNOS protein-protein interaction at glutamatergic synapses. The preclinical pharmacology of honokiol spans four principal domains. In oncology, honokiol inhibits proliferation, induces apoptosis through both intrinsic and extrinsic pathways, suppresses angiogenesis, and reduces metastatic potential in cell-line and xenograft models of breast, colon, prostate, lung, glioblastoma, and hematological malignancies, with demonstrated activity against NF-kB, STAT3, EGFR, and survivin signaling. In neuroprotection, honokiol preserves neuronal viability against amyloid-beta toxicity, glutamate excitotoxicity, and oxidative insult through SIRT3-dependent mitochondrial stabilization, reduction of reactive oxygen species, suppression of intracellular calcium elevation, and inhibition of caspase-3 activation. In anxiolysis and sedation, honokiol potentiates GABAergic neurotransmission at concentrations below those required for overt sedation, producing anxiolytic-like behavioral effects in rodent models without the tolerance, dependence, and amnesia liabilities associated with classical benzodiazepines. In inflammation, honokiol suppresses NF-kB-driven proinflammatory cytokine release, reduces glial activation in cerebral ischemia-reperfusion models, and attenuates inflammatory markers in models of sepsis, diabetic nephropathy, and postoperative cognitive decline. Pharmacokinetics in rodents are characterized by rapid oral absorption (time to peak plasma concentration approximately 20 minutes at 40 mg/kg in rats), extensive hepatic first-pass metabolism via glucuronidation and sulfation as the dominant biotransformation pathways, and limited oral bioavailability (reported values range from approximately 5 to 23 percent depending on formulation and species). The compound readily crosses the blood-brain barrier, a property that distinguishes it from many polyphenols of comparable molecular weight and that supports the observed central nervous system effects. The elimination half-life in rats after intravenous administration is approximately 49 to 56 minutes at doses of 5 to 10 mg/kg. The principal circulating species after oral administration is the monoglucuronide conjugate rather than free honokiol. Clinical evidence in humans is limited. A Phase I trial of liposomal honokiol in patients with relapsed or progressed malignant glioma reported safety, tolerability, and preliminary survival benefit with a dose-response relationship. Phase II trials of liposomal honokiol are ongoing in China. Magnolia bark extract containing honokiol has been evaluated in human supplementation trials at doses up to 500 mg daily for up to one year without reported adverse effects, though these preparations contain variable ratios of honokiol and its isomer magnolol. No regulatory authority has approved honokiol as a pharmaceutical agent. The compound is available as a dietary supplement ingredient in several jurisdictions and as a research-grade chemical from multiple suppliers. Investigators should obtain analytical confirmation of identity, purity, and honokiol-to-magnolol ratio on every lot. This monograph reviews the chemistry, isolation, and synthesis of honokiol; the multi-target molecular pharmacology in detail; the comprehensive rodent pharmacokinetic record; the preclinical pharmacology across oncology, neuroprotection, anxiolysis, and inflammation; the limited clinical evidence base; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a comparative assessment of five alternative compounds (magnolol, baicalein, resveratrol, curcumin, dihydrohonokiol-B) against honokiol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1479Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pterostilbene

    Plain-language summaryIntrigue 55 / 100

    Pterostilbene is a methylated cousin of resveratrol with substantially better oral bioavailability. It is found in blueberries and is sold as a longevity and cognitive supplement, often combined with NAD+ precursors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Dimethylated stilbenoid polyphenol and structural analog of resveratrol with enhanced oral bioavailability

    A naturally occurring trans-3,5-dimethoxy-4′-hydroxystilbene isolated from Pterocarpus heartwood and Vaccinium berries, distinguished from resveratrol by two methoxy substitutions that confer approximately fourfold greater lipophilicity, superior oral bioavailability, longer plasma half-life, and enhanced blood-brain barrier penetration while preserving SIRT1, AMPK, Nrf2, and NF-kappaB modulatory pharmacology.

    Abstract

    Pterostilbene (trans-3,5-dimethoxy-4′-hydroxystilbene; CAS 537-42-8; molecular formula C16H16O3; molecular weight 256.30 g/mol) is a dimethylated analog of resveratrol first isolated from Pterocarpus marsupium heartwood in 1940 and subsequently identified in Vaccinium corymbosum (blueberry), Vaccinium ashei (rabbiteye blueberry), Vitis vinifera (grape), and several other plant species. The two methoxy groups at the 3- and 5-positions of the A-ring replace two of the three free hydroxyl groups present in resveratrol, conferring approximately fourfold greater lipophilicity, substantially reduced first-pass glucuronidation and sulfation, oral bioavailability of approximately 60 to 80 percent (compared to approximately 20 percent for resveratrol), a plasma elimination half-life of approximately 105 minutes (compared to approximately 14 minutes for resveratrol), and enhanced penetration across the blood-brain barrier. These pharmacokinetic advantages have positioned pterostilbene as a bioavailability-optimized stilbenoid for research into the pleiotropic pharmacology shared with the broader stilbene class. The molecular pharmacology of pterostilbene centers on four principal signaling axes. First, pterostilbene activates sirtuin 1 (SIRT1) and downstream PGC-1alpha deacetylation, promoting mitochondrial biogenesis, fatty acid oxidation, and cellular stress resistance. Second, it activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis, promoting glucose uptake, and enhancing lipid catabolism. Third, it activates the Nrf2/Keap1 antioxidant response element pathway by directly disrupting the Keap1-Nrf2 protein-protein interaction and by epigenetic derepression of the Nrf2 promoter, inducing downstream expression of heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1), superoxide dismutase, and catalase. Fourth, it inhibits NF-kappaB and AP-1 transcriptional activity, attenuating pro-inflammatory mediator expression including inducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor alpha, and interleukin-1 beta. Additional preclinical activity includes modulation of PI3K/Akt/mTOR signaling in oncology models, induction of apoptosis and autophagy in multiple cancer cell lines, and anti-angiogenic effects through suppression of vascular endothelial growth factor and matrix metalloproteinase-9. The clinical evidence base for pterostilbene in humans is modest but growing. The principal randomized controlled trial (Riche et al., 2014) evaluated pterostilbene at 50 mg and 125 mg twice daily for 6 to 8 weeks in 80 hypercholesterolemic adults and reported significant reductions in systolic blood pressure (7.8 mmHg, p < 0.01) and diastolic blood pressure (7.3 mmHg, p < 0.001) at 250 mg/day, with no adverse effects on hepatic, renal, or glucose markers. The same trial identified a significant increase in low-density lipoprotein cholesterol (17.1 mg/dL, p = 0.001) with pterostilbene monotherapy, an effect attenuated by concurrent grape extract administration. A second major clinical program evaluated the combination of nicotinamide riboside and pterostilbene (NRPT, marketed as Basis by Elysium Health) in a randomized, double-blind, placebo-controlled trial of 120 healthy adults aged 60 to 80, demonstrating dose-dependent increases in whole blood NAD+ of approximately 40 percent at the recommended dose and approximately 90 percent at double dose after four weeks (Dellinger et al., 2017). Subsequent NRPT trials have reported reduction of hepatic inflammation markers in nonalcoholic fatty liver disease and safety in acute kidney injury. Preclinical pharmacology is extensive. In rodent models, pterostilbene at doses of 10 to 100 mg/kg has demonstrated neuroprotection in Alzheimer's disease models (aluminum chloride-induced, streptozotocin-induced, amyloid-beta 25-35-induced), improvement in spatial and working memory, antidiabetic activity through AMPK-mediated suppression of hepatic gluconeogenesis, anticancer activity across breast, colon, prostate, lung, gastric, pancreatic, and oral cancer cell lines and xenograft models, and anti-inflammatory activity in models of colitis, myocardial ischemia, and acute lung injury. The compound crosses the blood-brain barrier and has been characterized as a more potent neuromodulator than resveratrol at equivalent doses in aging and Alzheimer's disease models (Chang et al., 2012). Pterostilbene is commercially available as a dietary supplement and as a research-grade chemical from multiple suppliers. It is not approved as a pharmaceutical in any jurisdiction. The compound is generally recognized as safe at doses up to 250 mg/day based on the available human safety data, with the LDL cholesterol elevation representing the principal metabolic safety signal requiring monitoring. This monograph reviews the chemistry, natural sources, and synthesis of pterostilbene; the multi-target molecular pharmacology; pharmacokinetics and metabolism; the preclinical evidence base across neuroprotection, oncology, metabolic disease, and inflammation; the human clinical evidence; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety signals; and a comparative assessment of five stilbenoid and polyphenol alternatives against pterostilbene on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1480Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Palmitoylethanolamide (PEA)

    Endogenous N-acylethanolamide lipid mediator with peroxisome proliferator-activated receptor alpha agonism and mast cell modulatory activity

    An endogenous fatty acid amide biosynthesized from membrane phospholipids, identified as an anti-inflammatory factor in the 1950s and subsequently characterized as a peroxisome proliferator-activated receptor alpha agonist with broad analgesic, anti-inflammatory, neuroprotective, and mast cell stabilizing activity across chronic pain, neuroinflammation, and neurodegenerative disease models.

    Abstract

    Palmitoylethanolamide (PEA; CAS 544-31-0; molecular formula C18H37NO2; molecular weight 299.49 g/mol) is an endogenous fatty acid amide of the N-acylethanolamide class, biosynthesized on demand from membrane N-palmitoyl-phosphatidylethanolamine by the enzyme N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) and degraded principally by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase (NAAA) to palmitic acid and ethanolamine. The compound was first identified as a crystalline anti-inflammatory factor isolated from soybean lecithin by Kuehl et al. in 1957, following earlier observations by Coburn et al. (1954) that egg yolk protected against experimental anaphylactic arthritis. The Nobel laureate Rita Levi-Montalcini and colleagues subsequently characterized PEA as a modulator of mast cell degranulation and proposed the autacoid local injury antagonism (ALIA) mechanism in 1993, establishing the conceptual framework for PEA as an endogenous resolution factor in inflammation.

    The principal molecular target of PEA is the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha), at which PEA acts as a direct agonist with an EC50 of approximately 3.1 micromolar in cell-based reporter assays. Lo Verme et al. (2005) demonstrated that the anti-inflammatory actions of PEA in carrageenan-induced paw edema and phorbol ester-induced ear edema models are abolished in PPAR-alpha knockout mice, establishing PPAR-alpha as the principal mediator of PEA anti-inflammatory pharmacology. Additional receptor targets include the orphan G-protein coupled receptors GPR55 and GPR119, the transient receptor potential vanilloid type 1 channel (TRPV1, via indirect potentiation), and a mast cell surface receptor pharmacologically consistent with a peripheral cannabinoid site. PEA does not bind with meaningful affinity to classical cannabinoid receptors CB1 or CB2 but modulates the endocannabinoid system indirectly through an entourage mechanism: competition for FAAH-mediated degradation elevates tissue levels of the endocannabinoid anandamide, thereby potentiating anandamide signaling at CB1, CB2, and TRPV1.

    The clinical evidence base for PEA spans chronic pain, neuropathic pain, neuroinflammation, and neurodegenerative disease. A 2023 systematic review and meta-analysis of double-blind randomized controlled trials (Scuteri et al., Nutrients, 2023) encompassing 12 studies and approximately 1300 patients demonstrated that oral PEA at 300 to 1200 mg daily produces statistically significant and clinically meaningful pain intensity reduction compared to placebo or active control, with effect emerging at 30 days and increasing through 60 days of treatment. Specific indications with positive randomized controlled trial evidence include sciatic pain, diabetic peripheral neuropathy, carpal tunnel syndrome, temporomandibular joint disorder, chronic low back pain, endometriosis-associated pelvic pain, and fibromyalgia. Micronized (mPEA) and ultramicronized (umPEA) particle-size formulations have been developed to overcome the poor aqueous solubility and limited oral bioavailability of native crystalline PEA, with the micronization process increasing the specific surface area and producing substantially improved absorption and tissue distribution.

    PEA exhibits a favorable safety profile consistent with its status as an endogenous compound and a natural component of the human diet (present in egg yolk, soybean lecithin, peanut meal, and other food sources). Across more than 40 clinical studies and approximately 3000 patient-exposures, no serious adverse drug reactions have been attributed to PEA supplementation at doses up to 1200 mg daily for up to 120 days. The compound is marketed as a medical food or dietary supplement in multiple European jurisdictions (Normast, PeaPure, Levagen) and is available as a research-grade preparation from multiple chemical suppliers. PEA is not approved as a drug by the United States Food and Drug Administration or by the European Medicines Agency; its regulatory status varies by jurisdiction between dietary supplement, medical food, and food for special medical purposes.

    This monograph documents the chemistry, biosynthesis, and degradation of PEA; the multi-target molecular pharmacology including PPAR-alpha agonism, GPR55 and GPR119 signaling, mast cell modulation, and entourage potentiation of endocannabinoid tone; the pharmacokinetic profile with emphasis on formulation-dependent bioavailability; the preclinical pharmacology across pain, inflammation, and neurodegeneration models; the clinical evidence base in chronic and neuropathic pain, neuroinflammatory conditions, and neurodegenerative disease; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five alternative anti-inflammatory lipid mediators (cannabidiol, oleoylethanolamide, stearoylethanolamide, N-arachidonoylethanolamide, and resolvin E1) against PEA on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1494Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • AF710B

    Allosteric M1 muscarinic acetylcholine receptor agonist and sigma-1 receptor agonist with disease-modifying preclinical efficacy in Alzheimer’s disease models

    A dual-target allosteric M1 muscarinic and sigma-1 receptor agonist developed at the Israel Institute for Biological Research and advanced by Anavex Life Sciences as ANAVEX 3-71, distinguished from earlier orthosteric muscarinic agonists by allosteric M1 selectivity, picomolar-range potency, sigma-1 chaperone engagement, and disease-modifying activity across amyloid, tau, and neuroinflammatory pathologies in transgenic rodent models of Alzheimer’s disease.

    Abstract

    AF710B (ANAVEX 3-71) is a highly potent and selective allosteric agonist of the M1 subtype of the muscarinic acetylcholine receptor (M1 mAChR) and a concurrent agonist of the sigma-1 receptor (sigma-1R), first reported by Fisher et al. (2016) in Neurodegenerative Diseases as a next-generation candidate for cognitive enhancement and disease modification in Alzheimer’s disease [1]. The compound emerged from a decades-long medicinal chemistry program at the Israel Institute for Biological Research (IIBR) that previously produced the orthosteric M1 agonists AF102B (cevimeline, approved for Sjogren’s syndrome), AF267B, and AF292, each of which demonstrated procognitive and anti-amyloidogenic activity in preclinical and early clinical settings but was limited by insufficient M1 selectivity, dose-limiting cholinergic adverse events, or both. AF710B was designed to overcome these limitations through an allosteric mechanism of M1 receptor engagement: at nanomolar concentrations the compound potentiates the binding and efficacy of the endogenous agonist acetylcholine (and of the reference orthosteric agonist carbachol) at the M1 receptor, amplifying downstream signaling through phospho-ERK1/2 and phospho-CREB pathways without producing the gastrointestinal and cardiovascular cholinergic toxicity that constrained the earlier orthosteric series [1, 2]. Selectivity screening at 10 micromolar against 83 additional G-protein-coupled receptors, ion channels, and transporters produced no significant off-target hits, establishing a pharmacological selectivity profile substantially cleaner than that of xanomeline and other earlier M1-preferring agonists [1]. The sigma-1 receptor agonism adds a second, mechanistically independent neuroprotective axis. Sigma-1R is an endoplasmic reticulum chaperone protein concentrated at the mitochondria-associated endoplasmic reticulum membrane (MAM), where it regulates calcium transfer between the endoplasmic reticulum and mitochondria, modulates the unfolded protein response, and activates anti-inflammatory and antiapoptotic signaling cascades [3, 4]. Activation of sigma-1R by AF710B has been linked to rescue of mushroom spine loss in presenilin-1 knock-in and APP knock-in neuronal cultures, reduction of neuroinflammatory markers, and normalization of brain-derived neurotrophic factor (BDNF) signaling in transgenic models [1, 5]. In the seminal Fisher et al. (2016) study, AF710B administered to female 3xTg-AD mice at 10 micrograms per kilogram intraperitoneally daily for two months mitigated cognitive impairment in the Morris water maze and reduced BACE1 expression, GSK3-beta activity, p25/CDK5 levels, neuroinflammation, soluble and insoluble amyloid-beta 40 and 42, amyloid plaques, and phosphorylated tau pathology [1]. A subsequent study by Hall et al. (2018) in Alzheimer’s and Dementia extended these findings to the McGill-R-Thy1-APP transgenic rat model, demonstrating that chronic oral AF710B at 10 micrograms per kilogram daily for 4.5 months in 13-month-old (post-plaque) rats reversed cognitive deficits, reduced hippocampal amyloid plaque burden and cortical amyloid-beta 40 and 42 levels, decreased neuroinflammatory markers, increased cerebrospinal fluid amyloid clearance, and elevated the synaptic marker synaptophysin [6]. The disease-modifying character of the effect was underscored by its persistence through a five-week drug washout period following treatment cessation. A third study (Bhatt et al., 2024, Neurobiology of Aging) confirmed that early treatment with AF710B in the same rat model prevented cognitive decline when treatment was initiated before overt plaque deposition [7]. Anavex Life Sciences Corporation acquired exclusive worldwide rights to the AF710B intellectual property in 2014 and advanced the compound under the designation ANAVEX 3-71 through a first-in-human Phase 1 single ascending dose study in 42 healthy volunteers (2020 to 2021), which demonstrated safety and tolerability at oral doses of 5 to 200 mg with no serious adverse events, no clinically significant electrocardiogram changes, and linear, dose-proportional pharmacokinetics with a mean terminal elimination half-life of approximately 3.56 hours [8, 9]. A Phase 1b study subsequently confirmed the bioavailability of a once-daily oral tablet formulation. In 2024, Anavex initiated a placebo-controlled Phase 2 study (ANAVEX3-71-SZ-001) in adults with schizophrenia, and in October 2025 reported positive topline results demonstrating safety, tolerability, reduction in the neuroinflammatory biomarker glial fibrillary acidic protein (GFAP), and encouraging trends in EEG and event-related potential biomarkers [10, 11]. The compound has received orphan drug designation from the FDA for frontotemporal dementia. No registration-enabling Phase 3 trial has been completed for any indication as of the most recent monograph revision. This monograph documents the chemistry, synthesis, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing and handling considerations, stack interactions, adverse-event profile, and a structured comparative assessment of AF710B against five muscarinic and sigma-1 receptor candidates on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1456Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • EPI-743

    Para-benzoquinone 15-lipoxygenase inhibitor and redox-active cytoprotectant derived from alpha-tocotrienol quinone

    A synthetic vitamin E-derived para-benzoquinone developed by Edison Pharmaceuticals as a potent inhibitor of 15-lipoxygenase and augmenter of intracellular glutathione biosynthesis, advanced through clinical evaluation in Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other inherited mitochondrial respiratory chain diseases.

    Abstract

    EPI-743, now designated vatiquinone (INN) and previously referred to by the development codes PTC-743 and alpha-tocotrienol quinone, is a synthetic para-benzoquinone derived from the chromanone ring system of vitamin E (alpha-tocotrienol) that was identified in a phenotypic screen for small molecules capable of preventing oxidative cell death induced by L-buthionine-(S,R)-sulfoximine (BSO), an irreversible inhibitor of gamma-glutamylcysteine synthetase and therefore of de novo glutathione biosynthesis. The compound is approximately 1,000- to 10,000-fold more potent than coenzyme Q10 or idebenone in protecting mitochondrial disease and Friedreich ataxia patient fibroblasts in oxidative stress assays, a potency differential attributed to its capacity to serve as a substrate for NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) and thereby to replenish reduced intracellular glutathione and stabilize cellular redox balance. The mechanistic target has subsequently been identified as 15-lipoxygenase (15-LO), an oxidoreductase enzyme that catalyzes the peroxidation of polyunsaturated fatty acids under conditions of glutathione depletion or glutathione peroxidase 4 (GPX4) inactivation, a process now recognized as the lipid peroxidation arm of ferroptotic cell death. Vatiquinone is therefore classified as a first-in-class selective inhibitor of 15-lipoxygenase with secondary redox-modulatory activity through NQO1-dependent glutathione replenishment. The compound was discovered at Edison Pharmaceuticals (Mountain View, California), a company founded by Guy Miller and subsequently renamed BioElectron Technology Corporation in 2017. PTC Therapeutics acquired substantially all of BioElectron’s assets, including the vatiquinone program, in October 2019 for approximately $210 million. The clinical development program has spanned multiple inherited mitochondrial diseases and related conditions characterized by oxidative stress, mitochondrial dysfunction, and ferroptotic cell death. Open-label and emergency-protocol studies conducted between 2011 and 2017 evaluated EPI-743 in Leigh syndrome (Martinelli et al. 2012, ten pediatric patients, statistically significant reversal of disease progression on the Newcastle Pediatric Mitochondrial Disease Scale), in Leber hereditary optic neuropathy (Sadun et al. 2012, five patients, arrest of disease progression and reversal of visual loss in four of five subjects), in a heterogeneous cohort of genetically confirmed mitochondrial respiratory chain diseases (Enns et al. 2012, fourteen patients, clinical improvement in eleven of twelve survivors), and in Pearson syndrome. A Phase 2 study in Friedreich ataxia demonstrated safety and tolerability over two years. The pivotal registration-directed program is the Phase 3 MOVE-FA trial, a randomized, placebo-controlled, 72-week study in 146 pediatric and adult patients with Friedreich ataxia. The trial did not meet its primary endpoint of statistically significant change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS) in the primary analysis population (p = 0.14), though statistically significant effects were observed on the pre-specified upright stability subscale (p = 0.021) and in the per-protocol population (p < 0.05). Long-term extension data demonstrated a 3.7-point benefit on mFARS relative to a matched natural history cohort from the FACOMS disease registry at 144 weeks, representing a 50 percent slowing of disease progression over three years. PTC Therapeutics submitted a New Drug Application to the United States Food and Drug Administration, which granted Priority Review with a PDUFA target action date of August 19, 2025. The FDA subsequently issued a Complete Response Letter, indicating that additional efficacy data would be required to support approval. Pharmacokinetics are characterized by oral absorption with an effective half-life of approximately 9 hours, dose-proportional exposure across oral doses of 200 to 1,400 mg, CYP3A4-mediated hepatic metabolism, and lipophilic distribution consistent with the vitamin E-derived chemical structure. The compound is administered three times daily with food to enhance bioavailability. The safety profile across more than 500 patients and treatment durations of up to 10 years is favorable, with no treatment-related serious adverse events reported in key long-term studies. This monograph reviews the chemistry, synthesis, and structural pharmacology of EPI-743; the 15-lipoxygenase inhibition and NQO1-dependent redox mechanism in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other mitochondrial diseases; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative mitochondrial cytoprotectant or antioxidant compounds (idebenone, omaveloxolone, coenzyme Q10, elamipretide, and alpha-tocopherol) against EPI-743 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1468Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Nefiracetam

    Plain-language summaryIntrigue 45 / 100

    Nefiracetam is a dimethylphenyl racetam developed in Japan for cognitive impairment. Trials in post-stroke depression and apathy showed modest effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Fat-soluble pyrrolidinone racetam nootropic with multi-target modulation of GABAergic, cholinergic, and glutamatergic neurotransmission

    A lipophilic 2-oxopyrrolidinyl acetamide derived from the piracetam scaffold, developed by Daiichi Pharmaceutical as an antiamnesic agent for cerebrovascular dementia and distinguished from other racetams by concurrent modulation of GABA-A receptors, neuronal nicotinic acetylcholine receptors, voltage-gated calcium channels, and NMDA receptor function through convergent protein kinase C and CaM kinase II signaling.

    Abstract

    Nefiracetam (DM-9384, Translon), the N-(2,6-dimethylphenyl) acetamide derivative of 2-oxopyrrolidine and the most pharmacologically characterized fat-soluble member of the racetam nootropic class, is a cognition-enhancing agent developed by Daiichi Pharmaceutical (now Daiichi Sankyo) in Japan during the 1980s for the treatment of cognitive impairment secondary to cerebrovascular disease. Unlike the parent compound piracetam, which acts principally through membrane fluidity modulation and non-specific cholinergic facilitation, nefiracetam engages a convergent set of molecular targets: high-affinity interaction with the GABA-A receptor chloride channel complex (IC50 approximately 8.5 nM for displacement of [3H]muscimol binding), potentiation of neuronal nicotinic acetylcholine receptor currents through a G-protein-coupled protein kinase C pathway, enhancement of voltage-gated L-type and N-type calcium channel currents, potentiation of NMDA receptor function via protein kinase C activation with consequent reduction of the voltage-dependent magnesium block, and facilitation of hippocampal long-term potentiation through CaM kinase II and protein kinase C alpha activation downstream of NMDA receptor and metabotropic glutamate receptor 5 stimulation. The composite pharmacology produces a sustained facilitation of hippocampal synaptic transmission that resembles long-term potentiation and that depends on presynaptic nicotinic acetylcholine receptor activation and consequent glutamate release.

    Pharmacokinetics in healthy human volunteers are characterized by rapid oral absorption with peak plasma concentrations at approximately 1 to 2 hours, monophasic elimination with a plasma half-life of 3 to 5 hours, linear dose-proportional kinetics across the 100 to 900 mg range, negligible accumulation on repeated dosing, and principal hepatic metabolism through CYP3A4-mediated 5-hydroxylation of the pyrrolidine ring with a minor contribution from CYP1A2. Less than 10 percent of the administered dose is excreted unchanged in urine. The compound crosses the blood-brain barrier readily owing to its lipophilicity relative to piracetam.

    The clinical development program encompassed three principal indications. In cerebrovascular dementia, Phase 2 and Phase 3 trials conducted in Japan by Daiichi demonstrated cognitive improvement in patients with sequelae of cerebral infarction; however, a revised Phase 3 trial failed to meet its primary endpoint, and the New Drug Application was withdrawn in Japan in February 2002. In Alzheimer’s disease, the National Institute of Neurological Disorders and Stroke sponsored a randomized, double-blind, placebo-controlled Phase 2 trial (NCT00001933) evaluating nefiracetam at 600 mg and 900 mg daily for 20 weeks; preliminary reports indicated dose-dependent cognitive improvement in a subset of patients, but the program was not advanced to Phase 3. In poststroke depression and apathy, Robinson et al. (2008, 2009) conducted randomized controlled trials demonstrating that nefiracetam at 900 mg daily produced significant reduction in apathy scores in poststroke depressed patients, though the primary depression endpoint was not met; a subsequent confirmatory trial by Starkstein et al. (2016) for poststroke apathy did not replicate the benefit, possibly owing to insufficient statistical power.

    The compound is not approved in any jurisdiction as of the current monograph date. It is available as a research-grade preparation from multiple chemical suppliers. The principal preclinical toxicology concern is species-specific nephrotoxicity observed in dogs and rats attributable to a metabolite (M-18) that is not formed in humans or primates; long-term studies in humans and primates have not identified renal toxicity. This monograph reviews the chemistry, synthesis, and structural positioning of nefiracetam; the multi-target molecular pharmacology in mechanistic detail; the human pharmacokinetic record; the preclinical pharmacology across cognitive, anticonvulsant, and neuroprotective models; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a structured comparative assessment of five racetam-class nootropics against nefiracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1433Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • CDP-Choline

    Endogenous cytidine nucleotide intermediate in the Kennedy pathway of phosphatidylcholine biosynthesis with cholinergic, membranotropic, and neuroprotective activity

    An endogenous pyrophosphate-linked cytidine-choline conjugate that serves as the obligate intermediate in the de novo biosynthesis of phosphatidylcholine, administered exogenously as a neuroprotective and procognitive agent across stroke, traumatic brain injury, and age-related cognitive decline indications.

    Abstract

    Cytidine 5′-diphosphocholine (CDP-choline, citicoline) is an endogenous mononucleotide composed of cytidine and choline linked by a diphosphate bridge, functioning as the direct and obligate precursor to phosphatidylcholine in the Kennedy pathway of membrane phospholipid biosynthesis first characterized by Eugene P. Kennedy and Samuel B. Weiss in 1956. Exogenous administration of CDP-choline supplies the central nervous system with both choline (the substrate for acetylcholine synthesis and for phosphatidylcholine assembly) and cytidine (which is converted in human plasma to uridine, a pyrimidine nucleoside involved in synaptic glycoprotein synthesis and in the potentiation of nerve growth factor signaling). Oral bioavailability exceeds 90 percent in humans, and the compound is rapidly hydrolyzed in the intestinal wall and liver to its two circulating components, cytidine and choline, which cross the blood-brain barrier independently and are reassembled intracellularly by CTP:phosphocholine cytidylyltransferase, the rate-limiting enzyme of the Kennedy pathway. The pharmacological profile encompasses membrane phospholipid restoration, acetylcholine augmentation, dopaminergic modulation, attenuation of phospholipase A2-mediated arachidonic acid release, and preservation of cardiolipin and sphingomyelin content in ischemic neural tissue. These mechanisms collectively support the neuroprotective activity demonstrated in rodent models of focal and global cerebral ischemia, traumatic brain injury, and excitotoxic neuronal death.

    The clinical evidence base for CDP-choline spans more than 11,000 patients across multiple indications. In acute ischemic stroke, the compound was studied in the International Citicoline Trial on Acute Stroke (ICTUS), a 2,298-patient randomized, double-blind, placebo-controlled trial that produced a neutral primary endpoint (global recovery odds ratio 1.03, 95 percent confidence interval 0.86 to 1.25) but demonstrated benefit in prespecified subgroups including patients older than 70 years and those with less severe baseline deficits. An independent meta-analysis of ten randomized controlled trials subsequently reported a pooled odds ratio of 1.56 (95 percent confidence interval 1.12 to 2.16) favoring independence with citicoline treatment. In traumatic brain injury, the Citicoline Brain Injury Treatment Trial (COBRIT), a 1,213-patient Phase 3 trial published by Zafonte et al. in JAMA (2012), did not demonstrate benefit on functional or cognitive status at 90 days. In age-related cognitive impairment, a 2021 randomized controlled trial demonstrated significant improvement in episodic memory in healthy older adults after 12 weeks of oral supplementation at 500 mg daily. In chronic cerebrovascular disease, Cochrane meta-analysis identified positive short-term effects on memory and behavior, though evidence was limited by study duration and heterogeneity. The compound is registered as a pharmaceutical agent in over 60 countries for neurological indications (marketed as Somazina, Recognan, Ceraxon, and numerous generics) and is classified as a dietary supplement in the United States, where it has received Generally Recognized as Safe (GRAS) status. The toxicological profile is favorable: the oral LD50 in rats exceeds 2,000 mg/kg, no serious adverse events have been attributed to the compound in controlled trials, and adverse event rates in meta-analyses are comparable to placebo. This monograph reviews the chemistry, biosynthetic role, and stereochemistry of CDP-choline; the multitarget neuroprotective and cholinergic pharmacology; the complete pharmacokinetic record including the cytidine-to-uridine conversion unique to primates; the clinical evidence base across stroke, traumatic brain injury, cognitive impairment, glaucoma, and substance dependence indications; sourcing, reconstitution, and quality verification; stack interactions; adverse events and safety; and a comparative assessment of five alternative choline-pathway or membrane-trophic agents against CDP-choline on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1444Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Choline Bitartrate

    Plain-language summaryIntrigue 40 / 100

    Choline bitartrate is a basic salt form of choline used as a dietary choline supplement. It is the cheapest form of supplemental choline but with lower bioavailability than alpha-GPC or CDP-choline for brain delivery. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Quaternary ammonium salt delivering the essential nutrient choline as a bitartrate conjugate for acetylcholine precursor loading, phospholipid biosynthesis, and methyl-group donation

    A water-soluble tartaric acid salt of the essential nutrient choline, widely used as a dietary supplement to support acetylcholine synthesis, hepatic lipid export, and one-carbon methylation metabolism, distinguished from other choline donors by low cost, high aqueous solubility, and moderate oral bioavailability but limited blood-brain barrier penetration relative to phospholipid-conjugated choline sources.

    Abstract

    Choline bitartrate is the tartaric acid salt of choline, a quaternary ammonium compound recognized as an essential nutrient by the United States Institute of Medicine in 1998. The salt form contains approximately 41 percent choline by mass and is the most widely manufactured and least expensive choline supplement form in global commerce. Choline itself is a precursor to acetylcholine (synthesized by choline acetyltransferase from choline and acetyl-coenzyme A), to the membrane phospholipid phosphatidylcholine (synthesized by the cytidine diphosphate-choline or Kennedy pathway), and to the methyl donor betaine (synthesized by choline dehydrogenase and betaine aldehyde dehydrogenase in a two-step mitochondrial oxidation), which donates methyl groups to homocysteine in the betaine-homocysteine methyltransferase reaction. These three metabolic fates underwrite a broad physiological role that spans neurotransmission, membrane structural integrity, hepatic very-low-density lipoprotein assembly, one-carbon metabolism, and epigenetic regulation of gene expression through histone and DNA methylation. Pharmacokinetic studies in healthy volunteers demonstrate rapid oral absorption with peak plasma choline concentrations achieved within one to two hours after ingestion of a single dose. However, choline bitartrate delivers choline as the free water-soluble cation, which is subject to substantial first-pass hepatic extraction and gut microbial conversion to trimethylamine before systemic distribution. Gut microbial trimethylamine production and subsequent hepatic flavin-containing monooxygenase 3 oxidation to trimethylamine N-oxide represent both a metabolic loss pathway and a potential cardiovascular risk signal, as elevated circulating trimethylamine N-oxide concentrations have been associated with increased atherosclerotic cardiovascular disease incidence in prospective cohort studies. Compared to phospholipid-conjugated choline sources (alpha-glycerophosphocholine, cytidine diphosphate-choline, phosphatidylcholine from egg yolk or krill oil), choline bitartrate produces higher peak trimethylamine N-oxide levels and lower incremental phosphatidylcholine enrichment in plasma, reflecting differential metabolic routing. The clinical evidence base for choline bitartrate as a standalone supplement is mixed. Controlled feeding studies at the National Institutes of Health and at the University of North Carolina have established that dietary choline deprivation produces hepatic steatosis, elevated serum aminotransferase, and muscle damage in both men and women within weeks, confirming essentiality in humans. Epidemiological studies link higher dietary choline intake to reduced risk of nonalcoholic fatty liver disease and to reduced neural tube defect incidence in offspring of pregnant women. However, placebo-controlled trials of acute choline bitartrate supplementation in healthy young adults have failed to demonstrate significant enhancement of declarative memory or working memory, although improvements in visuomotor performance and pupil constriction have been reported. Chronic supplementation data in rodent models show cognitive and locomotor improvements accompanied by reduced oxidative stress. The evidence is more favorable for cognitive benefit in elderly populations and in individuals with diagnosed choline deficiency, consistent with the compound functioning as a conditional nootropic whose benefit depends on baseline choline status. The Institute of Medicine established Adequate Intake values of 550 mg per day for adult men and 425 mg per day for adult women, with 450 mg per day during pregnancy and 550 mg per day during lactation. The Tolerable Upper Intake Level for adults is 3500 mg of choline per day; adverse effects above the upper limit include hypotension, fishy body odor (from trimethylamine excretion), sweating, gastrointestinal distress, and hepatotoxicity. Population surveys indicate that the majority of adults in North America and Europe consume choline below the Adequate Intake, and fewer than 10 percent of pregnant women meet gestational requirements. This monograph reviews the chemistry, synthesis, and salt-form characteristics of choline bitartrate; the three-arm molecular pharmacology (acetylcholine synthesis, phospholipid biosynthesis, methyl donation); comprehensive pharmacokinetics including the trimethylamine N-oxide pathway; the clinical evidence base across cognitive, hepatic, gestational, and cardiovascular endpoints; sourcing and quality verification; reconstitution and handling; stack interactions with other cholinergic, nootropic, and hepatoprotective agents; adverse events and safety signals including the trimethylamine N-oxide cardiovascular association; and a comparative assessment of five alternative choline-delivery compounds (alpha-glycerophosphocholine, cytidine diphosphate-choline, phosphatidylcholine, choline chloride, and centrophenoxine) against choline bitartrate on five competency standards (bioavailability and brain penetration, effect size on cognitive endpoints, breadth of clinical evidence, side-effect profile, and cost-effectiveness).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1448Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pentadeca Arginate

    Arginate salt of the stable gastric pentadecapeptide BPC-157, a cytoprotective and tissue-regenerative 15-amino-acid oligopeptide

    An arginine-salt formulation of the gastric pentadecapeptide BPC-157 (Body Protection Compound-157) developed to improve oral bioavailability and acid stability, retaining the parent peptide’s pleiotropic cytoprotective, angiogenic, and tissue-regenerative pharmacology across gastrointestinal, musculoskeletal, and central nervous system research models.

    Abstract

    Pentadeca Arginate (PDA) is the arginate salt form of the stable gastric pentadecapeptide BPC-157 (Body Protection Compound-157, bepecin, PL 14736), a synthetic 15-amino-acid oligopeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of 1419.55 daltons (free base). The parent peptide was first characterized by Sikiric and colleagues at the University of Zagreb in 1993 as a partial sequence of a protein isolated from human gastric juice, and it has since accumulated a preclinical literature of more than 100 peer-reviewed publications demonstrating cytoprotective, pro-angiogenic, anti-inflammatory, and tissue-regenerative activity across gastrointestinal, musculoskeletal, hepatic, cardiovascular, and central nervous system injury models. The arginate salt formulation replaces the conventional acetate counterion with L-arginine, producing two pharmacologically consequential changes: first, a marked improvement in structural stability under simulated gastric acid conditions (greater than 95 percent structural integrity after five hours of gastric acid exposure, compared to less than 2 percent for the acetate form); and second, a reported increase in oral bioavailability of approximately 7-fold relative to the acetate salt, attributed to the arginine shielding of the peptide backbone from enzymatic degradation and the concurrent delivery of L-arginine as a nitric oxide synthase substrate that complements the parent peptide’s established nitric oxide system modulation. The pharmacology of Pentadeca Arginate is that of BPC-157, a pleiotropic cytoprotective agent whose principal characterized mechanisms include bidirectional modulation of nitric oxide production through the Akt-eNOS signaling axis; upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), epidermal growth factor receptor (EGFR), and growth hormone receptor expression; activation of extracellular signal-regulated kinase (ERK1/2) pathways driving fibroblast proliferation and collagen deposition; modulation of dopaminergic, serotonergic, and GABAergic neurotransmitter systems; and activation of early response gene cascades (Egr1, Akt1, Src, Nos3) within minutes of tissue injury. Preclinical pharmacokinetic characterization in rats and beagle dogs (Xu et al. 2022) demonstrated rapid absorption after intramuscular administration (Tmax approximately 3 minutes in rats, 6 to 9 minutes in dogs), a short plasma elimination half-life (approximately 15 minutes in rats, approximately 5 minutes in dogs), linear pharmacokinetics across studied dose ranges, and rapid metabolism to constituent amino acids through normal peptide degradation pathways. Human pharmacokinetic data remain extremely limited. Clinical evidence for BPC-157 in humans is confined to three pilot studies encompassing fewer than 30 total participants: a Phase I safety study in healthy volunteers (Veljaca et al. 2003), a Phase II enema study in ulcerative colitis (Ruenzi et al., unpublished full data), and recent intravenous safety studies (Lee and Burgess 2024, Lee et al. 2025) that reported no adverse events or clinically meaningful changes in cardiac, hepatic, renal, thyroid, or metabolic biomarkers at doses up to 20 mg. BPC-157 is not approved by any drug regulatory agency for human use. In September 2023, the United States Food and Drug Administration classified BPC-157 as a Category 2 bulk drug substance, prohibiting its use in compounding by 503A and 503B pharmacies. The World Anti-Doping Agency banned BPC-157 in 2022 under the S0 category of non-exempt substances. Pentadeca Arginate emerged in the clinical and compounding pharmacy market as an alternative formulation following the FDA Category 2 classification, leveraging the arginate salt distinction. This monograph reviews the chemistry, synthesis, and salt-form pharmacology of Pentadeca Arginate; the comprehensive preclinical pharmacology of the parent BPC-157 peptide across gastrointestinal, musculoskeletal, vascular, and central nervous system models; the limited human clinical evidence; sourcing and quality considerations; reconstitution and handling; stack-interaction implications; the adverse-event and safety profile; and a comparative assessment of five tissue-regenerative peptide candidates against Pentadeca Arginate on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1452Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Adrafinil

    Plain-language summaryIntrigue 50 / 100

    Adrafinil is the original eugeroic that the body converts to modafinil in the liver. It was sold in France as Olmifon for elderly daytime alertness before being discontinued in 2011. It is sold today as a research chemical because it is unscheduled in most jurisdictions. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Diphenylmethyl sulfinyl acetamide eugeroic; prodrug of modafinil with wakefulness-promoting activity

    A benzhydryl sulfinyl hydroxamic acid developed at Laboratoire Lafon as a vigilance-promoting agent for elderly patients, distinguished from classical psychostimulants by its prodrug relationship to modafinil and by a wakefulness mechanism mediated principally through atypical dopamine transporter inhibition and downstream orexinergic, histaminergic, and glutamatergic activation.

    Abstract

    Adrafinil (CRL-40028, Olmifon) is a synthetic diphenylmethyl sulfinyl hydroxamic acid compound and the first clinically introduced member of the eugeroic (wakefulness-promoting) pharmacological class, marketed in France from 1986 to 2011 for the treatment of inattention, drowsiness, and vigilance deficits in elderly patients. The compound functions as a prodrug: hepatic metabolism converts adrafinil to its primary active metabolite modafinil (CRL-40476, 2-diphenylmethylsulfinylacetamide), which was subsequently developed independently and received regulatory approval in the United States (1998), the European Union, and more than 20 additional jurisdictions for the treatment of narcolepsy, obstructive sleep apnea-associated excessive daytime sleepiness, and shift work sleep disorder. The prodrug conversion proceeds through enzymatic hydrolysis of the terminal hydroxamic acid to yield modafinil, with concurrent production of the inactive metabolite modafinilic acid (CRL-40467). The pharmacological activity of adrafinil is therefore substantially attributable to modafinil, an atypical dopamine reuptake inhibitor that binds the dopamine transporter (DAT) with low micromolar affinity (Ki approximately 2.3 micromolar) and produces wake-promoting effects through a cascade involving elevated extracellular dopamine, activation of D1 and D2 dopamine receptors, downstream stimulation of lateral hypothalamic orexin (hypocretin) neurons, secondary activation of tuberomammillary histaminergic projections, and modulation of cortical glutamatergic and GABAergic tone. Positron emission tomography studies in humans have demonstrated that modafinil at clinical doses occupies approximately 50 to 57 percent of striatal dopamine transporters, an occupancy level comparable to methylphenidate, though modafinil produces substantially less reinforcing subjective effects and lower abuse liability than classical psychostimulants. Clinical evidence for adrafinil itself is confined to six principal studies conducted in France between 1979 and the mid-1990s, predominantly in ambulatory and hospitalized elderly patients (aged 45 years and older, majority older than 65 years) exhibiting vigilance, attention, memory, and affective complaints. These studies reported improvements in attention, wakefulness, self-evaluated vigilance, depressive symptom scores, and functional autonomy, though the trial designs, outcome measures, and sample sizes did not meet the evidentiary standards that would later govern modafinil registration. The compound was voluntarily withdrawn from the French market in September 2011 following a regulatory review by the Commission d’Autorisation de Mise sur le Marche that concluded the clinical evidence was insufficient to establish benefit and that the known adverse effect profile, including hepatic enzyme elevations with chronic use and rare skin reactions, constituted an unfavorable risk-benefit ratio given the availability of modafinil as a more potent, better characterized, and directly acting alternative. Adrafinil is not a controlled substance in the United States, the United Kingdom, Canada, or most other jurisdictions, and is sold as an unregulated research compound and dietary supplement. This monograph reviews the chemistry, synthesis, and stereochemistry of adrafinil; the prodrug conversion and the molecular pharmacology of its active metabolite modafinil; the pharmacokinetic profile including hepatic biotransformation; the preclinical pharmacology in rodent, feline, and primate models; the clinical evidence base across vigilance, narcolepsy, and cognitive endpoints; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal including hepatotoxicity; and a structured comparative assessment of five wakefulness-promoting alternatives against adrafinil on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1437Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.